Knight Therapeutics (GUD) Earnings Date, Estimates & Call Transcripts → It’s now possible to know the win rate of every trade… BEFORE you take it! (From WealthPress) (Ad) Free GUD Stock Alerts C$5.69 -0.03 (-0.52%) (As of 04/25/2024 ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider Trades Earnings SummaryUpcoming Earnings DateMay. 9EstimatedActual EPS (Mar. 21) -C$0.03 Missed By -C$0.05 Consensus EPS (Mar. 21) C$0.02 Get Knight Therapeutics Earnings AlertsEnter your email address below to receive the latest news and earnings results for GUD and its competitors with MarketBeat's FREE daily newsletter. Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueGUD Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GUD Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad Stansberry ResearchWorld’s biggest multibillionaire investor is buying THIS by the ton [picture]Don't Buy Bullion or Mining Stocks. Do THIS Instead As gold continues to break all-time highs, many folks will run out and buy bullion or mining stocks. That's not the best way to ride this gold bull market higher. Note, this showed a 995% gain the last time we shared this same investment idea.Click here to find out what to do. Knight Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20241C($0.01)C($0.01)C($0.01)Q2 20241C$0.01C$0.01C$0.01Q3 20241C($0.01)C($0.01)C($0.01)Q4 20241C$0.00C$0.00C$0.00FY 20244C($0.01)C($0.01)C($0.01)Q1 20251C$0.00C$0.00C$0.00Q2 20251C$0.01C$0.01C$0.01Q3 20251C$0.01C$0.01C$0.01Q4 20251C$0.01C$0.01C$0.01FY 20254C$0.03C$0.03C$0.03GUD Earnings Date and InformationKnight Therapeutics last released its quarterly earnings results on March 21st, 2024. The reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C$0.05. The company had revenue of C$74.20 million for the quarter, compared to analysts' expectations of C$78.37 million. Knight Therapeutics has generated C($0.16) earnings per share over the last year (C($0.16) diluted earnings per share). Knight Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off prior year's report dates.Read More Knight Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript 5/9/2024Estimated)------- 3/21/2024Q4 2023C$0.02C($0.03)C($0.05)C$0.17C$78.37 millionC$74.20 million11/9/2023Q3 2023C$0.03C$0.09+C$0.06C$0.09C$72.00 millionC$81.50 million8/10/2023Q2 2023C$0.03C$0.02C($0.01)C$0.02C$80.15 millionC$89.91 million5/11/2023Q1 2023-C($0.04)C($0.04)C($0.04)C$74.80 millionC$82.60 million3/23/2023Q4 2022-C$0.02+C$0.02C$0.17C$62.00 millionC$81.66 million11/10/2022Q3 2022C($0.01)C$0.02+C$0.03C$0.03C$67.03 millionC$72.28 million Get the Latest News and Ratings for GUD and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 8/11/2022Q2 2022C$0.02C$0.02-C$0.02C$66.27 millionC$75.82 million5/12/2022Q1 2022C($0.04)C($0.02)+C$0.02C$0.12C$52.80 millionC$63.81 million3/24/2022Q4 2021-C($0.08)C($0.08)C($0.09)C$61.00 millionC$58.27 million11/11/2021Q3 2021C$0.03C$0.07+C$0.04C$0.21C$62.00 millionC$73.34 million5/14/2021Q1 2021C($0.02)C($0.03)C($0.01)C($0.09)C$52.50 millionC$46.07 million Knight Therapeutics Earnings - Frequently Asked Questions When is Knight Therapeutics's earnings date? Knight Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 9th, 2024 based off last year's report dates. Learn more on GUD's earnings history. Did Knight Therapeutics beat their earnings estimates last quarter? In the previous quarter, Knight Therapeutics (TSE:GUD) missed the analysts' consensus estimate of C$0.02 by C$0.05 with a reported earnings per share (EPS) of C($0.03). Learn more on analysts' earnings estimate vs. GUD's actual earnings. How much revenue does Knight Therapeutics generate each year? Knight Therapeutics (TSE:GUD) has a recorded annual revenue of C$328.20 million. How much profit does Knight Therapeutics generate each year? Knight Therapeutics (TSE:GUD) has a recorded net income of -C$16.84 million. GUD has generated -C$0.16 earnings per share over the last four quarters. What is Knight Therapeutics's price-to-earnings ratio? Knight Therapeutics (TSE:GUD) has a forward price-to-earnings ratio of 281.46. The price/earnings-to-growth ratio is -1013.5. More Earnings Resources from MarketBeat Related Companies: Aurora Cannabis Earnings Date Organigram Earnings Date Cipher Pharmaceuticals Earnings Date HLS Therapeutics Earnings Date Extendicare Earnings Date Viemed Healthcare Earnings Date Fennec Pharmaceuticals Earnings Date Opsens Earnings Date kneat.com Earnings Date Vitalhub Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: GE Aerospace is Ready for Liftoff After Strong EarningsTaiwan Semiconductor Earnings: AI Dominance and Future OutlookCSX Co.: The Railroad Powering Ahead with an Earnings Beat What's Driving Tesla Lower Ahead of its Earnings?Blackrock vs. State Street: Earnings in a Volatile MarketWhat to Expect From the Q1 Earnings Reporting SeasonLululemon Stock Implodes Post Earnings, Guidance Muted This page (TSE:GUD) was last updated on 4/25/2024 by MarketBeat.com Staff From Our PartnersFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsThe AI stock to buy right nowStockEarningsEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsKeep Your Eyes on This Power-Mad PoliticianAltimetryThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Knight Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
